Prescribers must complete e-learning ahead of Tinzaparin switch
From 1 September 2026, MFT is switching from Dalteparin to Tinzaparin for adult patients across all sites.
The change supports patient safety by introducing a single low molecular weight heparin (LMWH) suitable for patients with advanced renal impairment and also supports the Trust’s Value for Patients programme.
If you prescribe LMWH, you must complete the mandatory e-learning before go-live.
The training explains the rationale for the change, the new dosing regimen and what you need to know to prescribe Tinzaparin safely and confidently. It takes 20-30 minutes to complete.
The way Tinzaparin is prepared and administered differs from current practice. The 20-30 minute mandatory training explains the preparation and administration process and should be completed before go-live.
Pharmacy teams play a key role in supporting implementation, answering questions and ensuring colleagues are prepared for the switch. Additional training has already been provided to support local rollout.
Achieving at least 80% training compliance before go-live is critical. Please reinforce messages locally, support completion of training and encourage colleagues to prepare for the change.
Leave a Reply